Conditioned medium derived from mesenchymal stem cells overexpressing HPV16 E6E7 dramatically improves ischemic limb
Conditioned medium derived from mesenchymal stem cells overexpressing HPV16 E6E7 dramatically improves ischemic limb
复制标题
DOI:
10.1016/j.yjmcc.2014.04.012
复制
发表时间:
2014-07-01
影响因子:
5
通讯作者:
Hung, Shih-Chieh
中科院分区:
文献类型:
--
作者:
Chang, Ming-Chau;Tsao, Ching-Hua;Hung, Shih-Chieh
Mesenchymal stem cells (MSCs) have been shown to secrete cytokines and growth factors required for angiogenesis. Previously, we demonstrated that MSCs expressing HPV16 E6E7 mRNA (E6E7-MSCs) increase life span and differentiation potential and maintain without neoplastic transformation. Whether E6E7-MSCs are sources of molecules for enhancing angiogenesis is unknown. We demonstrated that E6E7-MSC-derived conditioned medium (E6E7-CM) enhanced endothelial cell migration and tube formation compared to primary MSC-derived conditioned medium (primary-CM). Moreover, E6E7-MSCs increased AKT activation and enhanced the release of Interleukin-1 beta (IL-1 beta) and vascular endothelial growth factor A (VEGFA). Neutralization of E6E7-CM with antibodies against IL-1 beta or VEGFA abrogated its effect in enhancing endothelial migration and tube formation. Primary-CM, added with IL-1 beta and VEGFA, enhanced its ability to increase endothelial migration and tube formation. E6E7-CM was shown to increase the ability to improve blood perfusion in a mouse limb ischemia model. Histological analysis revealed that E6E7-CM prohibited muscle loss or fibrosis and increased endothelial cell counts compared to primary-CM. Similarly, the effects of E6E7-CM in improving perfusion in ischemic limb were also contributed by the increase of IL-1 beta or VEGFA levels. These results suggest that E6E7-MSCs increase the ability to secrete angiogenic factors via Ala activation, and E6E7-CM is abundant in IL-1 beta and VEGFA levels and thereby increases the ability to improve blood perfusion and prohibit muscle loss or fibrosis in a mouse limb ischemia model. (C) 2014 Elsevier Ltd. All rights reserved.